October 8, 2023

Pharmashots: Addimmune to go Public via 10x Capital Venture Acquisition Corp. III SPAC Merger for ~$500M


View the full Article on:

Addimmune Summary

Addimmune Announces Public Offering via SPAC Merger

Addimmune, the HIV division of American Gene Technologies, is making significant strides toward its goal of delivering a gene therapy cure. This article highlights our upcoming merger with 10x Capital Venture Acquisition Corp. III, a special purpose acquisition company (SPAC). This transaction will allow Addimmune to go public, providing the resources necessary to accelerate the development of our groundbreaking HIV gene therapy.

Potential for a Transformative HIV Treatment

The proposed merger positions Addimmune for substantial growth, with an anticipated pre-money enterprise value of approximately $500 million. These funds will be crucial in advancing our innovative therapy, which has the potential to revolutionize HIV treatment.

We are optimistic about the future, driven by the compelling results of early trials. If successful, our HIV gene therapy promises to create a long-lasting solution for the millions of individuals living with HIV globally.